23 December 2025
23 December 2025
Shares rose 5% for Novo Nordisk as it looks to ease market pressures with a significant revenue stream.
From tariffs and onshoring to MFN, the US has seen significant policy developments - but how will these impact pharma in 2026?
The Amicus acquisition will bolster BioMarin’s rare disease portfolio, while potentially supporting the company’s revenue stream.
In this issue: M&A activity in 2025, China's drug licensing advance, the year ahead, and more.
Ipsen has become the latest Western pharma company to venture to China in search of ADC assets.
The authorisation follows similar greenlights in Europe and the US earlier this year.
Samsung Biologics will acquire the Rockville assets for $280m, with closing expected by the end of first quarter of 2026.
The FDA decision is supported by the GO29781 study in patients with third-line or later FL.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
